Mulmit

Viking Therapeutics, Inc.Viking Therapeutics, Inc.

VKTX Nasdaq

Annual financials

PeriodRevenueOperating incomeNet incomeEPS
2025-12-310-393,342,000-359,639,000-3.19
2024-12-310-150,921,000-109,963,000-1.01
2023-12-310-100,827,000-85,895,000-0.91
2022-12-310-70,355,000-68,867,000-0.9
2021-12-310-55,682,000-54,990,000-0.71

Insider filings (Forms 3/4/5)

DateOwnerTitleShares
2026-08-01Kelly-Gemmell Dorothy Elizabeth6,333
2026-08-01Kelly-Gemmell Dorothy Elizabeth40,800
2026-07-29Lian BrianPresident & CEO148,517
2026-07-29ZANTE GREGChief Financial Officer21,217
2026-07-29Mancini MariannaChief Operating Officer18,217
2026-07-28Lian BrianPresident & CEO221,667
2026-07-28ZANTE GREGChief Financial Officer31,667
2026-07-28Mancini MariannaChief Operating Officer31,667
2026-06-01Chen Hubert CChief Medical Officer190,000
2026-03-10Aubuchon Neil WilliamChief Commercial Officer4,475
2026-01-12Aubuchon Neil WilliamChief Commercial Officer180,000
2026-01-05ZANTE GREGChief Financial Officer31,961

8-K events

FiledItems
2026-07-29Results of operations · Financial statements and exhibits
2026-05-26Submission of matters to a vote · Financial statements and exhibits
2026-04-29Results of operations · Financial statements and exhibits
2026-02-11Results of operations · Financial statements and exhibits
2025-10-22Results of operations · Financial statements and exhibits
2025-08-19Regulation FD disclosure · Financial statements and exhibits
2025-07-23Results of operations · Financial statements and exhibits
2025-05-27Submission of matters to a vote · Financial statements and exhibits
데이터를 불러오는 중입니다…Loading…

가격 차트Price chart

차트를 불러오는 중입니다…Loading chart…